|
Pronunciation |
|
(en
KAY
nide) |
|
|
U.S. Brand
Names |
|
Enkaid® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Encainide Hydrochloride |
|
|
Pharmacological Index |
|
Antiarrhythmic Agent, Class I-C |
|
|
Use |
|
Ventricular arrhythmias; supraventricular arrhythmias |
|
|
Pregnancy Risk
Factor |
|
B |
|
|
Contraindications |
|
Hypersensitivity to encainide or any component; second or third degree A-V
block; premature ventricular complexes; nonsustained ventricular arrhythmias;
cardiogenic shock |
|
|
Adverse
Reactions |
|
>10%:
Central nervous system: Dizziness
Ocular: Blurred vision
1% to 10%:
Cardiovascular: Chest pain congestive heart failure, ventricular tachycardia
Central nervous system: Headache
Gastrointestinal: Vomiting
Neuromuscular & skeletal: Weakness
Otic: Tinnitus |
|
|
Drug
Interactions |
|
CYP2D6 enzyme substrate; beta-blockers (possible negative inotropic
effects) |
|
|
Usual Dosage |
|
Adults: Oral: 25 mg every 8 hours; may increase to 35 mg every 8 hours after
3-5 days if needed; increase to 50 mg every 8 hours in another 3-5 days if
response is not achieved |
|
|
Administration |
|
Give around-the-clock rather than 4 times/day, 3 times/day, etc (ie,
12-6-12-6, not 9-1-5-9) to promote less variation in peak and trough serum
levels |
|
|
Mental Health: Effects
on Mental Status |
|
Dizziness is common |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Use beta-blockers with caution; may produce additive negative inotropic
effect; caution with TCAs |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Take as directed; do not change dose except from advice of your physician;
report any chest pain and irregular heartbeats |
|
|
Dosage Forms |
|
Capsule, as hydrochloride: 25 mg, 35 mg, 50
mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|